DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPY

Eugenie S. Kleinerman; Diane Howser; Robert C. Young; Joan Bull; Leonard A. Zwelling; Audrey Barlock; Jean M. Decker; Andrew V. Muchmore

doi:10.1016/S0140-6736(80)92540-4

DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPY

Eugenie S. Kleinerman, Diane Howser, Robert C. Young, Joan Bull, Leonard A. Zwelling, Audrey Barlock, Jean M. Decker, Andrew V. Muchmore

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Spontaneous monocyte-mediated cytotoxity (SMMC) in 34 patients treated with a chemotherapeutic regimen including cisplatin for various malignancies was depressed (median 7% ⁵¹Cr release) compared with SMMC in 31 normal controls (median 43%; p<0·0001). Cytotoxicity in 7 patients with stage III or IV ovarian carcinoma was then followed during six cycles of chemotherapy with a cisplatin-containing regimen. All patients had initial cytotoxic values of <8%, and in all SMMC increased at least three-fold between the third and fifth cycle of chemotherapy. This study lends support to the concept that cancer patients have depressed monocyte function. Cisplatin-containing chemotherapy seems to enhance monocyte function in vitro and in vivo.

Original language	English (US)
Pages (from-to)	1102-1105
Number of pages	4
Journal	The Lancet
Volume	316
Issue number	8204
DOIs	https://doi.org/10.1016/S0140-6736(80)92540-4
State	Published - 1980
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(80)92540-4

Cite this

@article{15c34a8826fd4ceeb0a1b62bf2eb6bf3,

title = "DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPY",

abstract = "Spontaneous monocyte-mediated cytotoxity (SMMC) in 34 patients treated with a chemotherapeutic regimen including cisplatin for various malignancies was depressed (median 7% 51Cr release) compared with SMMC in 31 normal controls (median 43%; p<0·0001). Cytotoxicity in 7 patients with stage III or IV ovarian carcinoma was then followed during six cycles of chemotherapy with a cisplatin-containing regimen. All patients had initial cytotoxic values of <8%, and in all SMMC increased at least three-fold between the third and fifth cycle of chemotherapy. This study lends support to the concept that cancer patients have depressed monocyte function. Cisplatin-containing chemotherapy seems to enhance monocyte function in vitro and in vivo.",

author = "Kleinerman, {Eugenie S.} and Diane Howser and Young, {Robert C.} and Joan Bull and Zwelling, {Leonard A.} and Audrey Barlock and Decker, {Jean M.} and Muchmore, {Andrew V.}",

year = "1980",

doi = "10.1016/S0140-6736(80)92540-4",

language = "English (US)",

volume = "316",

pages = "1102--1105",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8204",

}

TY - JOUR

T1 - DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPY

AU - Kleinerman, Eugenie S.

AU - Howser, Diane

AU - Young, Robert C.

AU - Bull, Joan

AU - Zwelling, Leonard A.

AU - Barlock, Audrey

AU - Decker, Jean M.

AU - Muchmore, Andrew V.

PY - 1980

Y1 - 1980

N2 - Spontaneous monocyte-mediated cytotoxity (SMMC) in 34 patients treated with a chemotherapeutic regimen including cisplatin for various malignancies was depressed (median 7% 51Cr release) compared with SMMC in 31 normal controls (median 43%; p<0·0001). Cytotoxicity in 7 patients with stage III or IV ovarian carcinoma was then followed during six cycles of chemotherapy with a cisplatin-containing regimen. All patients had initial cytotoxic values of <8%, and in all SMMC increased at least three-fold between the third and fifth cycle of chemotherapy. This study lends support to the concept that cancer patients have depressed monocyte function. Cisplatin-containing chemotherapy seems to enhance monocyte function in vitro and in vivo.

AB - Spontaneous monocyte-mediated cytotoxity (SMMC) in 34 patients treated with a chemotherapeutic regimen including cisplatin for various malignancies was depressed (median 7% 51Cr release) compared with SMMC in 31 normal controls (median 43%; p<0·0001). Cytotoxicity in 7 patients with stage III or IV ovarian carcinoma was then followed during six cycles of chemotherapy with a cisplatin-containing regimen. All patients had initial cytotoxic values of <8%, and in all SMMC increased at least three-fold between the third and fifth cycle of chemotherapy. This study lends support to the concept that cancer patients have depressed monocyte function. Cisplatin-containing chemotherapy seems to enhance monocyte function in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0019127564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019127564&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(80)92540-4

DO - 10.1016/S0140-6736(80)92540-4

M3 - Article

C2 - 6107723

AN - SCOPUS:0019127564

SN - 0140-6736

VL - 316

SP - 1102

EP - 1105

JO - The Lancet

JF - The Lancet

IS - 8204

ER -

DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPY

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this